MORPHOSYS AG AUF DER ASH-JAHRESTAGUNG 2021 AKZEPTIERTE ABSTRACTS ZU TAFASITAMAB
Study Abstract Title Authors Status / Publication # /
Session
RE-MIND2 Tafasitamab plus Lenalidomide Grzegorz S. Nowakowski, Dok Hyun Yoon, Accepted as oral
versus pola-BR, R2, and CAR T: Patrizia Mondello, Erel Joffe, Anthea Peters, presentation
Comparing Outcomes from Isabelle Fleury, Richard Greil, Matthew Ku, #183
RE-MIND2, an Observational, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Session Name: 905.
Retrospective Cohort Study in Judith Trotman, Lorenzo Sabatelli, Dan Huang, Outcomes Research-Lymphoid
Relapsed/Refractory Diffuse Eva E. Waltl, Mark Winderlich, Sumeet Malignancies: Lymphoma/CLL
Large B-Cell Lymphoma Ambarkhane, Nuwan C. Kurukulasuriya, Raul Real-World Data
Cordoba, Georg Hess, Gilles Salles Session Date: Saturday,
December 11, 2021
Session Time: 12:00 PM -
1:30 PM
Presentation Time: 12:30
PM
Room: Georgia World
Congress Center, Sidney
Marcus Auditorium
Shared Preferences and Perceptions Mallory Yung, Frederick Schnell, Mirko Accepted as poster
Decision Regarding Treatment Vukcevic, Nuwan C. Kurukulasuriya (collaboration with
Making in R/R Decision-Making For Relapsed or Avalere) #1928
DLBCL Refractory Diffuse Large B-Cell Session Name: 902. Health
Lymphoma (R/R DLBCL) Services Research-Lymphoid
Malignancies: Poster I
Date: Saturday, December
11, 2021
Presentation Time: 5:30 PM
- 7:30 PM
Location: Georgia World
Congress Center, Hall B5
inMIND inMIND: A Phase 3 Study of Sehn L, Luminari S, Salar A, Wahlin B, Gopal Accepted as poster
(Inctye) Tafasitamab Plus Lenalidomide A, Bonnet C, Paneesha S, Trneny M, Manzke O, Session Name: 623. Mantle
and Rituximab Versus Placebo Seguy F, Li D, Hubel K, Scholz C Cell, Follicular, and
Plus Lenalidomide and Rituximab Other Indolent B Cell
for Relapsed/Refractory Lymphomas: Clinical and
Follicular or Marginal Zone Epidemiological: Poster II
Lymphoma Date: Sunday, December 12,
2021
Presentation Time: 6:00 PM
- 8:00 PM
Tafasitamab + The SUMOylation Inhibitor Maria Patra-Kneuer, Akito Nakamura, Keli Song, Accepted as poster
TAK981 TAK-981 in Combination with the Stephen Grossman, Andrea Polzer, Carmen #2268
preclinical CD19-Targeting Antibody Ginzel, Stefan Steidl, Allison J Berger, Igor Session Name: 605.
Tafasitamab Shows Enhanced Proscurshim, Christina Heitmüller Molecular Pharmacology and
Anti-Tumor Activity in Drug Resistance: Lymphoid
Preclinical B-Cell Lymphoma Neoplasms: Poster II
Models Date: Sunday, December 12,
2021
Presentation Time: 6:00 PM
- 8:00 PM
Location: Georgia World
Congress Center, Hall B5
Tafasitamab + The Impact of Prior Treatment Reona Sakemura, Claudia Manriquez Roman, Accepted as poster
CAR-T with a CD19 Targeting Paulina Horvei, Ekene Ogbodo, Erin E. (collaboration with Mayo
preclinical Monoclonal Antibody on Tapper,Elizabeth L. Siegler, Carli M. Stewart, Clinic)
Subsequent Treatment with CD19 Kendall J. Schick, Ismail Can, Mohamad M. #2412
Targeting CART Cell Therapy in Adada, Evandro D. Bezerra, Lionel Aurelien A. Session Name: 622.
Preclinical Models Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Lymphomas:
Ruff, Christian Augsberger, Jürgen Schanzer, Translational-Non-Genetic:
Maria Patra-Kneuer, Christina Heitmüller, Poster II
Stefan Steidl, Jan Endell, Wei Ding, Sameer A. Date: Sunday, December 12,
Parikh, Neil E. Kay, Greg Nowakowski, Michelle 2021
J. Cox, Saad S. Kenderian Presentation Time: 6:00 PM
- 8:00 PM
Location: Georgia World
Congress Center, Hall B5
First-MIND First-MIND: Primary Analysis David Belada, Katerina Kopeckova, Juan Miguel Accepted as poster
from a Phase Ib, Open-Label, Bergua Burgues, Don Stevens, Marc André, #3556
Randomized Study to Assess Ernesto Perez Persona, Petra Pichler, Philipp Session Name: 626.
Safety of Tafasitamab or Staber, Marek Trneny, Bettina Brackertz, Neha Aggressive Lymphomas:
Tafasitamab + Lenalidomide in Shah, Andrea Sporchia, John M. Burke, Grzegorz Prospective Therapeutic
Addition to R-CHOP in Patients S. Nowakowski Trials: Poster III
with Newly Diagnosed Diffuse Date: Monday, December 13,
Large B-cell Lymphoma 2021
Presentation Time: 6:00 PM
- 8:00 PM
Location: Georgia World
Congress Center, Hall B5
First-MIND Disease kinetics measured by Mouhamad Khouja, Anke Schillhabel, Michaela Accepted as poster with
MRD Analysis ctDNA correlates with treatment Kotrova, Nikos Darzentas, Christian Kuffer, short presentation
response after tafasitamab in Derek Blair, Monika Brüggemann, Christiane (collaboration with Univ.
combination with R-CHOP with or Pott of Kiel) / #3498
without lenalidomide in first Session Name: 621.
line treatment of DLBCL Lymphomas:
Translational-Molecular
and Genetic: Poster III
Date: Monday, December 13,
2021
Presentation Time: 6:00 PM (MORE TO FOLLOW) Dow Jones Newswires
November 04, 2021 09:00 ET (13:00 GMT)
